A new approach to pain research. Investigational. Not FDA-cleared or approved.
Biocurrent
ESLet’s connect

SCIENCE WITH PEOPLE AT ITS HEART

Life is bigger
than pain.

We’re developing a new approach to chronic pain. Guided by brain signals. Driven by curiosity. Built around people.

An investigational device. Clinical benefit remains under study.

A woman seated in Biocurrent’s research room
From our research communityPuerto Vallarta, México
A portrait extracted from a research-community video
A human question.

Could listening to the brain help us rethink pain research?

↘

OUR APPROACH

Listen.
Learn.
Keep asking.

Chronic pain is personal. Our research begins with that understanding.

Biocurrent brings together brain-signal sensing, software, and electrical stimulation through electrodes on the skin. We’re investigating how real-time feedback could guide stimulation for people living with chronic pain.

How the system works ↗
A seated person wearing an EEG headband in the research room
Research photography · EEG headband
01

A signal.
A question.
A place to begin.

THE SCIENCE, SIMPLY

A little feedback.
A different approach.

01

Listen to a signal

A headband records electrical activity from the scalp. This is called EEG. It supplies a signal to the software.

02

Adapt in real time

An AI model analyzes the signal and recommends changes to stimulation frequency, amplitude, timing, and waveform.

03

Study the response

Surface electrodes deliver alternating current through the skin. Researchers record pain scores before and immediately after a session.

The study does not establish how EEG changes relate to pain outcomes. The proposed mechanism remains under investigation.

OUR CLINICAL RESEARCH

Real questions.
Reported results.

Our company-reported Phase II study compared Biocurrent with standard interferential current therapy (ICT) at one research site in Puerto Vallarta. Both groups received electrical stimulation.

333participants
817sessions
30 minper session

Up to three sessions per participant. Company-provided manuscript dated September 24, 2026. Short-term observations, with no follow-up beyond the last session.

COMPANY-REPORTED PHASE II RESULTS

September 24, 2026

Participants reporting at least 50% lower pain

From baseline to the last observed immediate post-session score. Up to three sessions.

Biocurrent n = 22893.9%
Standard ICT n = 10558.1%
0100%

214 of 228 participants · 61 of 105 participants

Standard ICT is an active electrical-stimulation comparison, not an inert sham. These observations do not establish lasting relief, safety, or effectiveness.

See the results and their limits ↗

THE PEOPLE BEHIND THE RESEARCH

Every number
starts with a person.

A glimpse into our research community, through original photographs and still frames from recorded conversations. Thank you to everyone who makes this work possible.

Images document the research community. They are not testimonials, evidence of an individual’s response, or a promise of treatment results.

Biocurrent V6 device on the workbenchBIOCURRENT V6

FROM IDEA TO ENGINEERING

Science you
can see.

Behind the research is a real device, and a team working through the details. The V6 combines software-controlled stimulation with connected hardware.

Stimulation
Alternating current through surface electrodes
Feedback
EEG signals and software
Status
Investigational · In development

This is our current development hardware. It is not presented as the specific device used in the reported study. Not available for commercial sale.

Andrew Blount

WHY WE STARTED

A personal question.
A shared purpose.

Andrew Blount founded Biocurrent in 2020 after years of living with chronic pain. That experience became a question worth investigating, and a reason to bring people, engineering, and research together.

Andrew BlountFounder, Chairman & CEO

Dereck Villaseñor Toríz

Dereck Villaseñor Toríz

Clinical Trial Director

Sharon Pollack

Sharon Pollack

VP of Market Development

Alfred R. Berkeley III

Alfred R. Berkeley III

Board member · Former President of Nasdaq

Quynh Nguyen

Chief Technology Officer

Leading hardware and software engineering.

A FEW GOOD QUESTIONS

Curious?
Start here.

Can I buy or use Biocurrent?

Biocurrent is in development and is not available for commercial sale. This website does not offer treatment or enroll people in studies.

Is Biocurrent FDA-approved?

No. Biocurrent is not FDA-cleared or approved. Safety and effectiveness have not been established. We do not promise a regulatory pathway, decision, or launch date.

What do the Phase II results tell us?

The company manuscript reports immediate pain-score reductions in both groups, with larger reported changes in the Biocurrent group. The study does not establish lasting relief or effectiveness for other populations.

How can I learn more or collaborate?

Explore our research summary, then contact us about study materials, scientific collaboration, advisory roles, partnerships, or investment inquiries.

THE NEXT CHAPTER

Good questions.
Great conversations.

Curious about the science? Interested in collaborating or investing? We’d love to hear from you.

ablount@biocurrent.com ↗

For personal medical questions, please speak with your healthcare professional.

Please do not include medical records or personal health information.

Optional text-message updates

This form is for company inquiries. It does not enroll you in a trial or provide access to treatment.